Company intelligence / Profile preview

T-Cyte Therapeutics

Woodland, California, United States

Ownership: Private
Development stage: Other

Overview

T-Cyte Therapeutics is a biotechnology company specializing in the development of immunotherapeutics for veterinary medicine. The company is best known for its flagship product, the Lymphocyte T-Cell Immunomodulator (LTCI), which is the first and only USDA-approved treatment for Feline Leukemia Virus (FeLV) and Feline Immunodeficiency Virus (FIV). LTCI works by stimulating the production of CD4+ T-lymphocytes, thereby restoring immune function in cats suffering from chronic retroviral infections. In 2016, T-Cyte was acquired by Elanco Animal Health, which integrated the company's specialized feline health portfolio into its global veterinary offerings.

Therapeutic areas: Infectious Diseases
Modalities: BiologicProtein
Industry: Veterinary

Beyond the preview

Go deeper on T-Cyte Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on T-Cyte Therapeutics.

Explore the full profile